Abstract
Highly effective incretin-based therapies are increasingly extending beyond obesity treatment into fitness, body image, and sporting environments, raising new questions regarding athletes’ health, informed decision-making, performance enhancement, and off-label use. Direct extrapolation of evidence from obesity medicine to athletes is inappropriate because body mass management in sport must preserve training adaptation and physiological readiness for competition. This Perspective proposes Performance-Centred Weight Management (PCWM), a health-oriented conceptual framework intended to guide the evaluation of traditional weight-cutting practices, nutritional interventions, structured exercise programmes, incretin-based therapies, and future body mass interventions in sport. PCWM integrates five interdependent domains: muscle quality and function, energy availability, recovery and training adaptation, sport-specific performance capacity, and long-term athlete health and wellbeing, within a model of longitudinal monitoring aligned with training periodisation. PCWM distinguishes evaluation from endorsement. Rather than considering body mass reduction as the primary endpoint, the framework identifies physiological readiness for competition, athlete health, and informed decision-making as the principal outcomes of successful body mass management. By integrating performance-oriented assessment with medical supervision and harm-minimisation principles, PCWM offers a conceptual basis for evaluating emerging pharmacological body mass interventions. However, the framework has not yet undergone empirical validation, and its feasibility, clinical utility, and applicability across sporting disciplines require further investigation. Future research should examine off-label use, access pathways, risk perception, sport-specific physiological outcomes, and potential interactions between pharmacological appetite suppression, low energy availability, and training adaptation.